Osimertinib, marketed as Tagrisso, generated $5.08 billion in sales in 2022 [1].
How much did Tagrisso sell in the first quarter of 2023?
In the first quarter of 2023, Tagrisso sales reached $1.53 billion [2].
What is the projected future sales for Osimertinib?
While specific future sales projections are not detailed here, the drug's significant revenue in 2022 and early 2023 suggests continued market demand. Information on future sales trends and market analysis can be found at DrugPatentWatch.com [3].
What is Osimertinib used to treat?
Osimertinib is a targeted therapy for certain types of non-small cell lung cancer (NSCLC) [1]. It is specifically used for patients with epidermal growth factor receptor (EGFR) mutations [4].
When does the patent for Osimertinib expire?
The patent expiry date for Osimertinib is a critical factor for market competition, including the potential entry of generic versions. Details regarding patent timelines and exclusivity periods are available from sources like DrugPatentWatch.com [3].
What are the main competitors to Osimertinib?
The competitive landscape for EGFR-mutated NSCLC includes other targeted therapies. For instance, drugs like afatinib and erlotinib were earlier options, though Osimertinib has shown improved efficacy in specific patient populations [4]. Future competition may also arise from newer treatments in development or biosimilars once patents expire.